Print

Pearl Therapeutics Presents Dose-Ranging, Efficacy and Safety Results of PT003 as well as Components, PT001 and PT005 at American Thoracic Society Meeting  
5/17/2013 9:10:22 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

REDWOOD CITY, CALIF, May 17, 2013 (GLOBE NEWSWIRE) -- Pearl Therapeutics Inc. today announced that the Company would be presenting four posters at the upcoming annual meeting of the American Thoracic Society. In part, these presentations provide details of the doses selected for Phase 3 testing of PT003, the Company's fixed-dose combination of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist (LABA), delivered via a pressurized hydrofluoroalkane metered-dose inhaler (HFA MDI), as well as PT001 and PT005, the monotherapy components of PT003.

Help employers find you! Check out all the jobs and post your resume.

//-->